NcXHF

GENOMICS, PERSONALIZED MEDICINE, AND SUPPORTIVE CANCER CARE
References
1. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical
Oncology 2007 update of recommendations for the use of tumor
markers in breast cancer. J Clin Oncol. 2007;25:5287-5312.
2. Gradishar WJ, Anderson BO, Blair SL, et al. Breast cancer version 3.
2014. J Natl Compr Canc Netw. 2014;12:542-590.
3. daCosta DiBonaventura M, Copher R, Basurto E, et al. Patient preferences
and treatment adherence among women diagnosed with
metastatic breast cancer. Am Health Drug Benefıts. 2014;7:386-395.
4. Health Quality Ontario. Gene expression profıling for guiding adjuvant
chemotherapy decisions in women with early breast cancer: an
evidence-based and economic analysis. Ont Health Technol Assess Ser.
2010;10:1-57.
5. Cuffe S, Hon H, Qiu X, et al. Cancer patients acceptance, understanding,
and willingness-to-pay for pharmacogenomic testing. Pharmacogenet
Genomics. 2014;24:348-355.
6. Kuchuk N, Bouganim N, Beusterien K, et al. Preference weights for chemotherapy
side effects from the perspective of women with breast cancer.
Breast Cancer Res Treat. 2013;142:101-107.
7. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments
of side effects from chemotherapy: insights from experienced patients
with ovarian cancer. Support Care Cancer. 2005;13:219-227.
8. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis
after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:
2590-2598.
9. Shah RR. Pharmacogenetics in drug regulation: promise, potential and
pitfalls. Philos Trans R Soc Lond B Biol Sci. 2005;360:1617-1638.
10. Pirmohamed M. Personalized pharmacogenomics: predicting effıcacy
and adverse drug reactions. Annu Rev Genomics Hum Genet. 2014;15:
349-370.
11. Papanastasopoulos P, Stebbing J. Molecular basis of 5-fluorouracilrelated
toxicity: lessons from clinical practice. Anticancer Res. 2014;34:
1531-1535.
12. Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of
5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG
N0147). J Natl Cancer Inst. 2014;106:298.
13. Saif MW, Lee AM, Offer SM, et al. A DPYD variant (Y186C) specifıc to
individuals of African descent in a patient with life-threatening 5-FU
toxic effects: potential for individualized medicine approach. Mayo Clin
Proc. 2014;89:131-136.
14. Beier MT, Panchapagesan M, Carmen LE. Pharmacogenetics: has the
time come for pharmacists to embrace and implement the science. Consult
Pharm. 2013;28:696-711.
15. van Staveren MC, Guchelaar HJ, van Kuilenburg ABP, et al. Evaluation
of predictive tests for screening for dihydropyrimidine dehydrogenase
defıciency. Pharmacogenomics J. 2013;13:389-395.
16. Hertz DL, Rae J. Pharmacogenetics of cancer drugs. Annu Rev Med.
2015;66:65-81.
17. Bosó V, Herrero MJ, Santaballa A, et al. SNPs and taxane toxicity in
breast cancer patients. Pharmacogenomics. 2014;15:1845-1858.
18. Roco A, Cayún J, Contreras S, et al. Can pharmacogenetics explain effıcacy
and safety of cisplatin pharmacotherapy? Front Genet. Epub 2014
Nov 14.
19. Gervasini G, Vagace JM. Impact of genetic polymorphisms on chemotherapy
toxicity in childhood acute lymphoblastic leukemia. Front
Genet. Epub 2012 Nov 22.
20. den Hoed MA, Lopez-Lopez E, Te Winkel ML, et al. Genetic and metabolic
determinants of methotrexate-induced mucositis in pediatric
acute lymphoblastic leukemia. Pharmacogenomics J. Epub 2014 Nov 4.
21. Csordas K, Lautner-Csorba O, Semsei AF, et al. Associations of novel
genetic variations in the folate-related and ARID5B genes with the pharmacokinetics
and toxicity of high-dose methotrexate in paediatric acute
lymphoblastic leukemia. Br J Haematol. 2014;166:410-420.
22. Russi EG, Raber-Durlacher JE, Sonis ST. Local and systemic pathogenesis
and consequences of regimen-induced inflammatory responses in
patients with head and neck cancer receiving chemoradiation. Mediators
Inflamm. 2014;518261.
23. Wardill HR, Van Sebille YZ, Mander KA, et al. Toll-like receptor 4 signaling:
a common biological mechanism of regimen-related toxicities:
an emerging hypothesis for neuropathy and gastrointestinal toxicity.
Cancer Treat Rev. 2015;41:122-128.
24. Sonis ST, Schwartzberg LS, Weidner SM, et al. From Bayesian modeling
to genomic mapping: biologic validity of predictive single nucleotide
polymorphism networks for chemotherapy-related side effects. J Clin
Oncol. 2013;31 (suppl; abstr 9535).
25. Alsbeih G, El-Sebaie M, Al-Harbi N, et al. SNPs in genes implicated in
radiation response are associated with radiotoxicity and evoke roles as
predictive and prognostic biomarkers. Radiat Oncol. 2013;8:125.
26. Gustafson HL, Yao S, Goldman BH, et al. Genetic polymorphisms in
oxidative stress-related genes are associated with outcomes following
treatment for aggressive B-cell non-Hodgkin lymphoma. Am J Hematol.
2014;89:639-645.
27. Bogunia-Kubik K, Polak M, Lange A. TNF polymorphisms are associated
with toxic but not with aGVHD complications in the recipients of
allogeneic sibling hematopoietic stem cell transplantation. Bone Marrow
Transplant. 2003;32:617-622.
28. Schirmer MA, Mergler CP, Rave-Fränk M, et al. Acute toxicity of radiochemotherapy
in rectal cancer patients: a risk particularly for carriers
of the TGFB1 Pro25 variant. Int J Radiat Oncol Biol Phys. 2012;83:
149-157.
29. Werbrouck J, De Ruyck K, Duprez F, et al. Acute normal tissue reactions
in head-and-neck cancer patients treated with IMRT: influence of dose
and association with genetic polymorphisms in DNA DSB repair genes.
Int J Radiat Oncol Biol Phys. 2009;73:1187-1195.
30. Della-Morte D, Riondino S, Ferroni P, et al. Impact of VEGF gene polymorphisms
in elderly cancer patients: clinical outcome and toxicity.
Pharmacogenomics. 2015;16:61-78.
31. Barnett GC, Coles CE, Elliott RM, et al. Independent validation of genes
and polymorphisms reported to be associated with radiation toxicity: a
prospective analysis study. Lancet Oncol. 2012;13:65-77.
32. Corvin A, Craddock N, Sullivan PF. Genome-wide association studies: a
primer. Psychol Med. 2010;40:1063-1077.
33. Jewell NP. Statistics for Epidemiology. Boca Raton: CRC Press; 2004.
34. Tucker SL, Li M, Xu T, et al. Incorporating single-nucleotide polymorphisms
into the Lyman model to improve prediction of radiation pneumonitis.
Int J Radiat Oncol Biol Phys. 2013;85:251-257.
35. Tragante V, Moore JH, Asselbergs FW. The ENCODE project and perspectives
on pathways. Genet Epidemiol. 2014;38:275-280.
36. Hoh J, Ott J. Mathematical multi-locus approaches to localizing complex
human trait genes. Nat Rev Genet. 2003;4:701-709.
37. Gabriel SB, Salomon R, Pelet A, et al. Segregating at three loci explains
familial and population risk in Hirschsprung disease. Nat Genet. 2002;
31:89-93.
38. Saligan LN, Fernández-Martinez JL, deAndrés-Galiana EJ, et al. Supervised
classifıcation by fılter methods and recursive feature elimination
predicts risk of radiotherapy-related fatigue in patients with prostate
cancer. Cancer Inform. 2014;13:141-152.
39. Sonis S, Antin J, Tedaldi M, et al. SNP-based Bayesian networks can
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK 15